DESTINY PHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.5 GBX | -1.73% |
|
-12.82% | -87.86% |
| 06-18 | Destiny Pharma presents "exciting" data for ringworm drug | AN |
| 06-12 | EARNINGS AND TRADING: Intuitive Investments NAV rises, talks up Hui10 | AN |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 18.86 | 40.97 | 62.87 | 39.22 | 66.69 | 8.141 | - |
| Enterprise Value (EV) 1 | 11.36 | 31.23 | 58.22 | 34.32 | 60.31 | 6.59 | 8.141 |
| P/E ratio | -4.02 x | -5.71 x | -11.8 x | -5.75 x | -11.3 x | -1.42 x | -1.02 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 61.7 x | - | 629 x | - | 80.2 x | - | - |
| EV / Revenue | 37.1 x | - | 582 x | - | 72.5 x | - | - |
| EV / EBITDA | - | -4.78 x | -9.28 x | -4.78 x | -10.1 x | -0.99 x | - |
| EV / FCF | - | -5.68 x | -11.4 x | -5.82 x | -11 x | -1.16 x | - |
| FCF Yield | - | -17.6% | -8.8% | -17.2% | -9.08% | -86.2% | - |
| Price to Book | - | 3.29 x | 8.37 x | 5.14 x | 7.25 x | 2.44 x | - |
| Nbr of stocks (in thousands) | 43,865 | 59,817 | 59,872 | 73,307 | 95,272 | 95,771 | - |
| Reference price 2 | 0.4300 | 0.6850 | 1.050 | 0.5350 | 0.7000 | 0.0865 | 0.0865 |
| Announcement Date | 29/04/20 | 14/04/21 | 12/04/22 | 13/04/23 | 25/04/24 | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.3059 | - | 0.1 | - | 0.8316 | - | - |
| EBITDA 1 | - | -6.536 | -6.274 | -7.178 | -5.971 | -6.661 | - |
| EBIT 1 | -5.585 | -6.553 | -6.287 | -7.776 | -6.736 | -6.416 | -8 |
| Operating Margin | -1,825.62% | - | -6,286.95% | - | -810.05% | - | - |
| Earnings before Tax (EBT) 1 | -5.521 | -6.481 | -6.271 | -7.712 | -6.446 | -6.387 | - |
| Net income 1 | -4.708 | -5.411 | -5.339 | -6.504 | -5.657 | -5.618 | -8 |
| Net margin | -1,539.02% | - | -5,339.48% | - | -680.3% | - | - |
| EPS 2 | -0.1070 | -0.1200 | -0.0890 | -0.0930 | -0.0620 | -0.0610 | -0.0850 |
| Free Cash Flow 1 | - | -5.494 | -5.121 | -5.893 | -5.475 | -5.682 | - |
| FCF margin | - | - | -5,120.69% | - | -658.44% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 29/04/20 | 14/04/21 | 12/04/22 | 13/04/23 | 25/04/24 | - | - |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 7.5 | 9.74 | 4.65 | 4.9 | 6.38 | 1.55 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -5.49 | -5.12 | -5.89 | -5.48 | -5.68 | - |
| ROE (net income / shareholders' equity) | - | -53.6% | -53.5% | -85.9% | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 0.2100 | 0.1300 | 0.1000 | 0.1000 | 0.0400 | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | 0.02 | 0 | 0.03 | 0 | 0 | 0 | - |
| Capex / Sales | 6.85% | - | 30.26% | - | 0.1% | - | - |
| Announcement Date | 29/04/20 | 14/04/21 | 12/04/22 | 13/04/23 | 25/04/24 | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0865
GBP
Average target price
1.883
GBP
Spread / Average Target
+2,077.26%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -87.86% | 10.5M | |
| +15.58% | 122B | |
| +16.60% | 113B | |
| +17.55% | 26.22B | |
| -24.33% | 19.01B | |
| -19.14% | 15.71B | |
| -17.95% | 15.22B | |
| -46.81% | 14.72B | |
| +58.78% | 14.58B | |
| +4.91% | 13.84B |
- Stock Market
- Equities
- DEST Stock
- Financials Destiny Pharma plc
